The wholesale cost for Vertex’s twice-daily medicine is set at $15.50 per 50 milligram tablet. Vertex’s drug was approved to treat moderate-to-severe acute pain. The company has been pushing ...
Hosted on MSN1mon
Vertex gets FDA approval for non-opioid pain relieverShares of Vertex Pharmaceuticals (NASDAQ ... The agency approved Journavx 50 milligram oral tablets for the treatment of moderate to severe acute pain in adults. The drug had also been granted ...
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
Journavx costs $15.50 per 50 mg tablet, taken twice daily, making it pricier than opioids. Vertex's Q4 sales hit $2.91 billion, up 16% YoY, beating the $2.78 billion consensus. Next: Get access to ...
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel non-opioid pain medication. This approval marks ...
StockStory.org on MSN3d
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The PackLet’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback